SCHEMBL22863373

SCHEMBL22863373

Cc1cccc(C)c1Cn1ccc2c(C(C)(C)O)cc(-c3cn(C)c4c(=O)[nH]ccc34)cc21

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 19/20 0.69
TRIM24 O15164 1/20 0.44
BRD1 O95696 1/20 0.44
TAF1 P21675 1/20 0.44
BRD2 P25440 1/20 0.44
BRPF1 P55201 1/20 0.44
EP300 Q09472 1/20 0.44
BRD3 Q15059 1/20 0.44
BRDT Q58F21 1/20 0.44
PBRM1 Q86U86 1/20 0.44
TAF1L Q8IZX4 1/20 0.44
CREBBP Q92793 1/20 0.44
CECR2 Q9BXF3 1/20 0.44
BRD8 Q9H0E9 1/20 0.44
BRD9 Q9H8M2 1/20 0.44
BAZ2A Q9UIF9 1/20 0.44
KCNH2 Q12809 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29777112 0.94 BRD4 (0.62) BRD4TRIM24BRD1TAF1BRD2
SCHEMBL22863349 0.94 BRD4 (0.62) BRD4TRIM24BRD1TAF1BRD2
SCHEMBL22863535 0.92 BRD4 (0.58) BRD4TRIM24BRD1TAF1BRD2
SCHEMBL22863419 0.86 BRD4 (0.70) BRD4TRIM24BRD1TAF1BRD2
SCHEMBL22863302 0.83 BRD4 (0.61) BRD4TRIM24BRD1TAF1BRD2
SCHEMBL22863303 0.83 BRD4 (0.61) BRD4TRIM24BRD1TAF1BRD2
SCHEMBL22863351 0.82 BRD4 (0.59) BRD4TRIM24BRD1TAF1BRD2
SCHEMBL22863352 0.82 BRD4 (0.59) BRD4TRIM24BRD1TAF1BRD2
SCHEMBL22863344 0.80 BRD4 (0.70) BRD4TRIM24BRD1TAF1BRD2
SCHEMBL22863524 0.79 BRD4 (0.70) BRD4TRIM24BRD1TAF1BRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11840533-B2 Pyridinone-based epigenetic modifiers and uses thereof THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2023-12-12 US disclosed
US-11840533-B2 Pyridinone-based epigenetic modifiers and uses thereof THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2023-12-12 US disclosed
US-11840533-B2 Pyridinone-based epigenetic modifiers and uses thereof THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2023-12-12 US disclosed
US-20220289742-A1 PYRIDINONE-BASED EPIGENETIC MODIFIERS AND USES THEREOF UNIV ILLINOIS (US) 2022-09-15 US disclosed
US-11332466-B2 Pyridinone-based epigenetic modifiers and uses thereof THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2022-05-17 US disclosed
US-11332466-B2 Pyridinone-based epigenetic modifiers and uses thereof THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2022-05-17 US disclosed
US-20210002272-A1 PYRIDINONE-BASED EPIGENETIC MODIFIERS AND USES THEREOF UNIV ILLINOIS (US) 2021-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210002272-A1 PYRIDINONE-BASED EPIGENETIC MODIFIERS AND USES THEREOF BRD1, BRD2, BRD3 BRD4 5/4885TRIM24 629/4885BRD1 1/4885
US-11332466-B2 Pyridinone-based epigenetic modifiers and uses thereof BRD1, BRD2, BRD3 BRD4 5/4885TRIM24 629/4885BRD1 1/4885
US-20220289742-A1 PYRIDINONE-BASED EPIGENETIC MODIFIERS AND USES THEREOF BRD1, BRD2, BRD3 BRD4 5/4885TRIM24 629/4885BRD1 1/4885
US-11840533-B2 Pyridinone-based epigenetic modifiers and uses thereof BRD1, BRD2, BRD3 BRD4 5/4885TRIM24 629/4885BRD1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.